Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC (“Future Pak”) to acquire the Company.
| No Shareholder Action Required at This Time WASHINGTON, May 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC (“Future Pak”) to acquire the Company. The revised proposal consists of a $7.25 to $7.75 per share in cash plus certain Contingent Value Rights (“CVRs”). The amended proposal follows Vanda’s review and rejection of a prior unsolicited proposal from Future Pak to acquire the Company for $7.25-$7.75 per share.
Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, Vanda’s Board of Directors will carefully review and evaluate the revised unsolicited proposal to determine the course of action that it believes is in the best interests of Vanda and its shareholders. Vanda does not intend to comment further on the revised, unsolicited proposal before the Board has completed its review. There is no action for shareholders to take at this time. About Vanda Pharmaceuticals Inc. Vanda Corporate Contact: Jim Golden / Jack Kelleher / Dan Moore
SOURCE Vanda Pharmaceuticals Inc. | ||
Company Codes: NASDAQ-NMS:VNDA |
View original content to download multimedia:
